Flexion Therapeutics (FLXN) Shares Sold by Bamco Inc. NY

Bamco Inc. NY cut its holdings in shares of Flexion Therapeutics (NASDAQ:FLXN) by 22.1% during the 1st quarter, according to its most recent Form 13F filing with the SEC. The firm owned 176,300 shares of the specialty pharmaceutical company’s stock after selling 50,000 shares during the period. Bamco Inc. NY owned 0.47% of Flexion Therapeutics worth $3,951,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also bought and sold shares of FLXN. Wells Fargo & Company MN increased its stake in shares of Flexion Therapeutics by 1,024.1% during the fourth quarter. Wells Fargo & Company MN now owns 1,706,942 shares of the specialty pharmaceutical company’s stock valued at $42,742,000 after buying an additional 1,555,093 shares during the period. BlackRock Inc. increased its stake in shares of Flexion Therapeutics by 17.4% during the fourth quarter. BlackRock Inc. now owns 2,650,986 shares of the specialty pharmaceutical company’s stock valued at $66,381,000 after buying an additional 392,055 shares during the period. Perceptive Advisors LLC purchased a new position in shares of Flexion Therapeutics during the fourth quarter valued at approximately $7,712,000. Ardsley Advisory Partners increased its stake in shares of Flexion Therapeutics by 137.1% during the fourth quarter. Ardsley Advisory Partners now owns 415,000 shares of the specialty pharmaceutical company’s stock valued at $10,392,000 after buying an additional 240,000 shares during the period. Finally, American Financial Group Inc. purchased a new position in shares of Flexion Therapeutics during the fourth quarter valued at approximately $5,280,000. 97.05% of the stock is currently owned by hedge funds and other institutional investors.

Several equities analysts have recently issued reports on the company. BidaskClub raised Flexion Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday. BMO Capital Markets reissued an “outperform” rating and set a $36.00 target price (down from $37.00) on shares of Flexion Therapeutics in a research note on Friday, March 9th. ValuEngine raised Flexion Therapeutics from a “hold” rating to a “buy” rating in a research note on Friday, April 27th. Wells Fargo reaffirmed a “buy” rating on shares of Flexion Therapeutics in a research note on Thursday, April 26th. Finally, Zacks Investment Research raised Flexion Therapeutics from a “sell” rating to a “hold” rating in a research note on Friday, May 11th. Three research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company. Flexion Therapeutics currently has a consensus rating of “Buy” and an average target price of $99.00.

Shares of FLXN stock opened at $27.49 on Tuesday. The firm has a market capitalization of $1.04 billion, a P/E ratio of -6.61 and a beta of 0.82. Flexion Therapeutics has a twelve month low of $16.51 and a twelve month high of $32.25. The company has a debt-to-equity ratio of 0.67, a quick ratio of 15.47 and a current ratio of 15.57.

Flexion Therapeutics (NASDAQ:FLXN) last issued its quarterly earnings results on Tuesday, May 8th. The specialty pharmaceutical company reported ($1.10) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($1.33) by $0.23. The firm had revenue of $2.19 million during the quarter, compared to analysts’ expectations of $1.99 million. equities analysts anticipate that Flexion Therapeutics will post -4.74 earnings per share for the current fiscal year.

Flexion Therapeutics Profile

Flexion Therapeutics, Inc, a biopharmaceutical company, focuses on the development and commercialization of anti-inflammatory and analgesic therapies for the treatment of patients with musculoskeletal conditions. It lead product candidate includes Zilretta, an intra-articular injection for the management of osteoarthritis (OA) pain of the knee.

Institutional Ownership by Quarter for Flexion Therapeutics (NASDAQ:FLXN)

Receive News & Ratings for Flexion Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Flexion Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply